Investor Optimism Improves After US Stocks Settle Slightly Higher

The CNN Money Fear and Greed index showed some improvement in the overall market sentiment on Friday. U.S stocks closed slightly higher on Friday, but recorded losses for the week. The Dow Jones declined around 0.2% last week, snapping a four-week winning streak.

The CNN Money Fear and Greed index showed some improvement in the overall market sentiment on Friday.

U.S stocks closed slightly higher on Friday, but recorded losses for the week. The Dow Jones declined around 0.2% last week, snapping a four-week winning streak.

The Procter & Gamble Company (NYSE:PG) shares gained 3.5% on Friday after the company reported better-than-expected Q3 results and raised its FY23 all-in sales guidance.

HCA Healthcare, Inc. (NYSE:HCA) shares gained around 4% on Friday after the company reported strong Q1 results and revised FY23 guidance.

The Dow Jones closed higher by around 22 points to 33,808.96 on Friday. The S&P 500 rose 0.09% at 4,133.52, while the Nasdaq Composite rose 0.11% to settle at 12,072.46 during the session.

Investors are awaiting earnings results from The Coca-Cola Company (NYSE:KO), Whirlpool Corporation (NYSE:WHR) and First Republic Bank (NYSE:FRC) today.

At a current reading of 65.0, the index remained in the “Greed” zone, versus a previous reading of 64.0

What is CNN Business Fear & Greed Index?

The Fear & Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.

Read Next: Top 4 Risk Off Stocks That Are Preparing To Pump This Month

Total
0
Shares
Related Posts
Read More

Novartis Announced Investigational Oral Monotherapy Iptacopan Demonstrates Clinically Meaningful Superiority over Anti-C5 Treatment in Phase III APPLY-PNH sStudy

Novartis today announced the pivotal Phase III APPLY-PNH trial met its two primary endpoints, showing investigational oral monotherapy iptacopan was superior to anti-C5 therapies (eculizumab or ravulizumab) in adults with paroxysmal nocturnal hemoglobinuria (PNH) experiencing residual anemia despite prior treatment with anti-C5s1.

NVS

Read More

Goldman Sachs Downgrades Chegg To Sell, Cites Rising Competition From Gen-Z Using AI

The downgrade reflects worries about Chegg's ability to expand its subscriber base amid heightened competition at lower price points, with increasing investments in AI initiatives, including integrating generative AI, affecting near-term margins and investor confidence in 2024.

CHGG